ADPT Adaptive Biotechnologies

Q: Which ETFs hold ADPT?

Adaptive Biotechnologies (ADPT) is held by 1 fund tracked by ETFpeek as of 9 Oct 2026: ARKG (2.32%).

Which ETFs hold ADPT? Adaptive Biotechnologies is held by 1 fund tracked by ETFpeek.

Held by 1 fund todayData as of 9 Oct 2026

HealthcareDiagnostics & Research

$26.09

+72.0% 1y

$12.0052-week range$30.74

Market cap

$4.5B

3-month

+23.9%

CEO

Mr. Chad M. Robins M.B.A.

Revenue · last 4 qtrs (+21.5% YoY)

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Currently Held By

ARK

ARKG

ARK Genomic Revolution ETF

Not held by the selected provider.

Insider Activity i

last 90 days

Net flow (90d):−$12.0M·9 BUY / 14 SELL·score ≥ 40

Date	Person	Action	Plan	Shares	Value	Score i
1 Oct 2026	Francis Lo Chief People Officer	SELL	Unknown	18,698	$535K	50
21 Jul 2026	Harlan S Robins Director / Other	SELL	Unknown	492,400 2 tranches	$10.8M	70
15 Jul 2026	Francis Lo Chief People Officer	SELL	Unknown	105,762	$2.4M	90

Net flow (90d):−$12.0M·9 BUY / 14 SELL·showing all trades

Date	Person	Action	Plan	Shares	Value	Score i
5 Oct 2026	Julie Rubinstein President & COO	BUY	Option Exercise	11,881	$144K	0
5 Oct 2026	Julie Rubinstein President & COO	SELL	Unknown	11,881 2 tranches	$347K	0
2 Oct 2026	Julie Rubinstein President & COO	BUY	Option Exercise	11,881	$144K	0
2 Oct 2026	Julie Rubinstein President & COO	SELL	Unknown	11,881	$334K	0
1 Oct 2026	Francis Lo Chief People Officer	SELL	Unknown	26,792 2 tranches	$758K	50
1 Oct 2026	Julie Rubinstein President & COO	BUY	Option Exercise	11,881	$144K	0
1 Oct 2026	Julie Rubinstein President & COO	SELL	Unknown	11,881 2 tranches	$333K	0
1 Oct 2026	Francis Lo Chief People Officer	BUY	Option Exercise	17,415 2 tranches	$144K	0
26 Aug 2026	Katey Einterz Owen Director / Other	SELL	Unknown	9,615	$250K	0
10 Aug 2026	Susan Bobulsky Chief Commercial Officer of MRD	SELL	Unknown	3,000	$75K	30
30 Jul 2026	Susan Bobulsky Chief Commercial Officer of MRD	SELL	Unknown	1,299	$31K	30
21 Jul 2026	Harlan S Robins Director / Other	SELL	Unknown	492,400 2 tranches	$10.8M	70
21 Jul 2026	Harlan S Robins Director / Other	BUY	Option Exercise	284,800	$1.9M	0
16 Jul 2026	Susan Bobulsky Chief Commercial Officer of MRD	SELL	Unknown	5,000	$115K	30
15 Jul 2026	Francis Lo Chief People Officer	SELL	Unknown	105,762	$2.4M	90
15 Jul 2026	Francis Lo Chief People Officer	BUY	Option Exercise	105,762 3 tranches	$943K	0

Data: Finnhub (SEC Form 4 filings) · Score: ETFpeek heuristic

Trade History

3 trades

Date	Fund	Direction	Shares Changed	% Δ ETF i	% Δ Position i
10 Jul 2026	ARKG	SELLReduced	-108,120	-0.01%	5.77%
9 Jul 2026	ARKG	SELLReduced	-32,771	-0.08%	1.72%
8 Jul 2026	ARKG	SELLReduced	-72,324	-0.11%	3.62%
No trade history for SmartShares funds — their underlying ETFs are passive index trackers, so day-to-day rebalancing is minimal.

ADPT Adaptive Biotechnologies

Currently Held By

Insider Activity i

Trade History

More stocks in these funds